Analysis – Goldea Capital

Aspo Plc: Share repurchase 29.12.2025

Written by Customer Service on December 29, 2025. Posted in Public Companies.

Aspo Plc ANNOUNCEMENT 29.12.2025 Aspo Plc: Share repurchase 29.12.2025 In the Helsinki Stock Exchange Trade date 29.12.2025 Bourse trade Buy Share ASPO Amount 2 500 SharesAverage price/ share 6,4720 EURTotal cost 16 180,00 EUR Aspo Plc now holds a total of 105 500 shares including the shares repurchased on 29.12.2025 The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052. On behalf of Aspo Plc Nordea Bank Oyj Sami Huttunen Ilari Isomäki For more information, please contact: Erkka...

Information release calendar for 2026

Written by Customer Service on December 29, 2025. Posted in Public Companies.

Interim information of Grigeo Group AB will be prepared and financial results will be released on these dates: February 25, 2026 – Interim Financial Statements for 12 months of 2025.April 7, 2026 – Annual audited Financial Statements for the year 2025.May 25, 2026 – Interim Financial Statements for 3 months of 2026.August 25, 2026 – Interim Financial Statements for 6 months of 2026.November 24, 2026 – Interim Financial Statements for 9 months of 2026. On April 30, 2026, the Company plans to hold an ordinary general meeting of shareholders. Tomas JozonisChief Executive Officer+370 5 243 58 01

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Written by Customer Service on December 29, 2025. Posted in Public Companies.

Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001’s Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON’s position. Our focus on harnessing the power to activate the body’s immune system against cancer has yielded compelling results, bringing us closer to delivering innovative therapies that could transform patient outcomes and create substantial...

Davis Commodities Evaluates China & North Asia Scale-Up Strategy in Multi-Billion-Dollar Sweeteners Market

Written by Customer Service on December 29, 2025. Posted in Public Companies.

SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) — Davis Commodities Limited (“Davis Commodities” or the “Company”) announced that it is evaluating a strategic scale-up framework for China and North Asia, supported by the assessment of sugar-based, value-added sweeteners positioned for expanding consumption channels and industrial food applications. This initiative forms part of the Company’s ongoing review of potential downstream integration opportunities, regional diversification strategies, and pathways to build scalable, higher-value growth platforms. Positioning Toward a Multi-Billion-Dollar Demand Environment China and broader North Asia continue to represent one of the world’s most active sweetener consumption ecosystems, supported by: •Expanding middle-class consumption patterns•Growth in beverage and packaged-food innovation...

WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026

Written by Customer Service on December 29, 2025. Posted in Public Companies.

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. (“Hunan Saitumofei”) has entered into a one-year exclusive distribution agreement (the “Agreement”) with Shanghai Benke Medical Technology Co., Ltd. (“Shanghai Benke”) to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the “Analyzer”) in East China throughout 2026. The collaboration is expected to accelerate market access and drive large-scale commercialization of the new product. Pursuant to the Agreement,...

XBP Global Partners with a Leading Property and Casualty Insurance Organization to Transform Payment Processing Through AI-Driven Automation

Written by Customer Service on December 29, 2025. Posted in Public Companies.

IRVING, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, announced a strategic, multi-year partnership with a leading U.S. based property and casualty (P&C) insurance provider. The engagement, valued at approximately $24 million over five years, will modernize the insurer’s payment ecosystem through XBP’s intelligent, automation solutions. As part of the partnership, XBP will deploy its advanced AI-driven and RPA-infused automation platform to digitize and streamline end-to-end payment operations specifically designed for the P&C insurance processing. A key component of this transformation...

Charging Robotics: Revoltz Successfully Demonstrates PORTO Micro-EV to an Israeli Government Entity for Potential Urban Applications

Written by Customer Service on December 29, 2025. Posted in Public Companies.

Tel Aviv, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) — Charging Robotics Inc. (OTC: CHEV), today announced that its subsidiary, Revoltz Ltd. (of which Charging Robotics owns 51.07%), has successfully presented and demonstrated its flagship PORTO electric micro-mobility vehicle to representatives of an Israeli government entity The demonstration highlights the PORTO’s potential to transform last-mile delivery operations in urban environments with efficient, sustainable, and agile transportation. Revoltz, specializing in high-end mini electric vehicles that bridge traditional automotive design with innovative micro-mobility solutions, showcased the PORTO – a compact, three-wheeled electric cargo vehicle engineered specifically for last-mile logistics. Key features of the PORTO include:Exceptional cargo capacity comparable to...

Apranga Group investor’s calendar for the year 2026

Written by Customer Service on December 29, 2025. Posted in Public Companies.

The expected company releases and investor news of Apranga Group in 2026 will be announced as follows: 05.01.2026 – Retail turnover in December 202502.02.2026 – Retail turnover in January 202627.02.2026 – Interim information for 12 months 202502.03.2026 – Retail turnover in February 202601.04.2026 – Retail turnover in March 202603.04.2026 – Notice on General shareholders’ meeting29.04.2026 – Interim information for 3 months 202630.04.2026 – General shareholders’ meeting30.04.2026 – Annual information for 202502.05.2026 – Retail turnover in April 202602.06.2026 – Retail turnover in May 202601.07.2026 – Retail turnover in June 202629.07.2026 – Interim report for 6 months 202601.08.2026 – Retail turnover in July 202601.09.2026 – Retail turnover in August...

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Written by Customer Service on December 29, 2025. Posted in Mergers And Acquisitions.

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio. Earthvision Bio has developed and are commercializing a new category of sustainable products created by Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, who was board chairman for Chevron Europe. The Company...

ECD Automotive Design Launches Luxury Agent Program to Expand Sales Reach and Drive Production Growth

Written by Customer Service on December 29, 2025. Posted in Public Companies.

New Sales Channel Builds on 2026 Product Expansion and Advances Factory Utilization Strategy KISSIMMEE, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (“ECD” or the “Company”) (NASDAQ: ECDA), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs, and Toyota FJs, today announced the launch of its Luxury Agent Program, a new sales channel designed to complement the Company’s existing direct-to-consumer strategy, expand market reach, and increase production. Under the Luxury Agent Program, ECD will partner with select U.S.-based luxury and exotic automotive advisors, including dealers and professionals (the “Luxury Agents”) deeply embedded in the high-net-worth and collector vehicle ecosystem. These...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals